In December 2016, Bristol-Myers Squibb was granted exclusive worldwide rights to NG-348. PsiOxus will lead pre-IND activities and Bristol-Myers Squibb is responsible for all clinical development and commercialization. View the partnership announcement.
In June 2016, Bristol-Myers Squibb and PsiOxus partnered on a clinical collaboration to evaluate Enadenotucirev in combination with nivolumab to investigate their use in several tumor types (the SPICE study). View the collaboration announcement.